中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.03 seconds)

    METHODS AND COMPOSITIONS FOR ASSESSING LUNG GRAFTS
    12.
    发明公开
    METHODS AND COMPOSITIONS FOR ASSESSING LUNG GRAFTS 审中-公开

    公开(公告)号：EP3809139A1

    公开(公告)日：2021-04-21

    申请号：EP20198785.6

    申请日：2014-02-20

    Applicant: University Health Network

    Inventor： KESHAVJEE, Shaf ,  LIU, Mingyao ,  CYPEL, Marcelo

    IPC: G01N33/68

    Abstract: A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising:
    a) collecting a test sample from the lung graft;
    b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD);
    c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate for transplant.

    METHODS OF MEASURING IL-6 EXPRESSION TO DETERMINE RISK OF CHRONIC ALLOGRAFT LING DYSFUNCTION
    17.
    发明公开
    METHODS OF MEASURING IL-6 EXPRESSION TO DETERMINE RISK OF CHRONIC ALLOGRAFT LING DYSFUNCTION 审中-公开
    法测量确定用于慢性肺移植功能障碍同种异体的风险的IL-6表达的抑制

    公开(公告)号：EP2959017A1

    公开(公告)日：2015-12-30

    申请号：EP14754331.8

    申请日：2014-02-20

    Applicant: University Health Network

    Inventor： KESHAVJEE, Shaf ,  LIU, Mingyao ,  CYPEL, Marcelo

    IPC: C12Q1/68 ,  G01N33/48 ,  G01N33/53 ,  G06F19/20

    CPC classification number: C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/6869 ,  G01N2333/4727 ,  G01N2333/5412 ,  G01N2333/5428 ,  G01N2800/245 ,  G01N2800/50

    Abstract: Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b. assessing the likelihood of the donor lung developing BOS subtype CLAD or RAS subtype CLAD post-transplant based on said IL-6, S100, optionally S100A8 and/or S100A9, expression level wherein IL-6 expression level is positively correlated with an increased likelihood of developing BOS post-transplant, S100A8 expression level is positively correlated with having or having an increased likelihood of developing RAS and/or BOS subtype CLAD, and S100A9 is positively correlated with having and having an increased likelihood of developing RAS subtype CLAD.

    Abstract translation: 用于测定用于慢性同种异体移植肺机能障碍（CLAD）任选闭塞性细支气管炎综合征（BOS）亚型或限制性同种异体移植综合征（RAS）亚型CLAD的或显影BOS亚型或RAS亚型CLAD移植后的方法，包括的风险中的供体肺的方法： 一。 测量供体肺移植前或一种或多种S100蛋白的标准化的表达水平，任选S100A8和/或S100A9，多肽表达产物的样品其在IL-6或表达产物的RNA转录物的归一化的表达水平 从供体肺移植后的样品中; 湾 assesing供体肺显影BOS亚型包覆或基于所述IL-6，S100，任选S100A8和/或S100A9，表达水平worin IL-6表达水平与在增加的可能性正相关RAS亚型CLAD移植后的可能性 显影BOS移植后，S100A8表达水平正与具有或具有发展RAS和/或BOS亚型CLAD的可能性增加相关，S100A9正与具有和具有发展RAS亚型CLAD的可能性增加相关。

    METHODS TO DETERMINE RISK OF CHRONIC ALLOGRAFT LUNG DYSFUNCTION
    19.
    发明公开
    METHODS TO DETERMINE RISK OF CHRONIC ALLOGRAFT LUNG DYSFUNCTION 审中-公开

    公开(公告)号：EP3653724A9

    公开(公告)日：2021-02-24

    申请号：EP19197128.2

    申请日：2014-02-20

    Applicant: University Health Network

    Inventor： KESHAVJEE, Shaf ,  LIU, Mingyao ,  CYPEL, Marcelo

    IPC: C12Q1/68 ,  G01N33/48 ,  G01N33/53 ,  C12Q1/6883

    Abstract: Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising:
    a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant;
    b. assessing the likelihood of the donor lung developing BOS subtype CLAD or RAS subtype CLAD post-transplant based on said IL-6, S100, optionally S100A8 and/or S100A9, expression level wherein IL-6 expression level is positively correlated with an increased likelihood of developing BOS post-transplant, S100A8 expression level is positively correlated with having or having an increased likelihood of developing RAS and/or BOS subtype CLAD, and S100A9 is positively correlated with having and having an increased likelihood of developing RAS subtype CLAD.

Patent Agency Ranking